Investing3d
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential
Key findings include: A 50% cumulative major molecular response (MMR) rate in non-T315I patients Reductions in BCR::ABL1 transcripts in 88% of MR1+ patients Significant responses observed post ...
Investing3d
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential
Key findings include: A 50% cumulative major molecular response (MMR) rate in non-T315I patients Reductions in BCR::ABL1 transcripts in 88% of MR1+ patients Significant responses observed ...
pharmaphorum5d
Novartis eyes New Year verdict from FDA on delayed Leqvio
previously treated with two or more tyrosine kinase inhibitors (TKIs), as well as patients harbouring the T315I mutation. Novartis picked up a breakthrough designation for the drug in February on ...